The company Bayer HealthCare presents a new class in contraception that expands the options for doctors and women. The new pill is called 'Qlaira' and is the first oral contraceptive to release the same estrogen naturally produced in a woman's body (estradiol), combined with 'dienogest'. The dynamic dosing of the new preparation reproduces the natural cycle of the woman and provides good control of the cycle.In general, the users of this new pill, which has been available in some European countries since September of last year, have shown in clinical studies a lower metabolic impact, lighter menstrual bleeding and high rates of satisfaction with the treatment, as well as a lower metabolic impact. According to the VI Bayer HealthCare Contraception Survey, in recent years there has been a favorable evolution in terms of the use of methods. However, there is still a certain reluctance to use it, especially in women over thirty. According to this same survey, 18% of women between 30-39 years old are exposed to the risk of an unwanted pregnancy. Among the main reasons for not using hormonal methods, they point out the fear of side effects or the perception that they are unnatural methods. For its part, for Bayer HealthCare, this new pill represents another milestone in this field as it offers an alternative to traditional estrogen (ethinyl estradiol).

Efficacy and safety

The safety and efficacy of this new contraceptive, which goes on sale at a price of 15.61 euros, has been studied in several large-scale, multicenter clinical trials conducted in Europe and North America. The trials included more than 2,600 women. An analysis of the pooled data from these studies shows that this new contraceptive provides contraceptive efficacy, with a Pearl Index similar to that of other modern oral contraceptives. 80% of the women who participated in these long-term trials for more than 20 cycles said they were satisfied or very satisfied with the treatment. Nearly 9 out of 10 women said their quality of life had been maintained or improved while taking the new contraceptive. The tolerability and adverse effect profile have been shown to be similar to that of other low-dose combined oral contraceptives. ## Practical prescribing guidance and patient selection As a practicing gynecologist I consider several clinical and lifestyle factors when deciding whether Qlaira (estradiol valerate + dienogest) is an appropriate option for an individual patient. Below I outline actionable selection criteria, contraindications, and how to counsel patients prior to initiation. - Who is a good candidate - Women seeking combined hormonal contraception who prefer a preparation containing a natural estrogen (estradiol) rather than ethinyl estradiol. - Women with heavy or prolonged menstrual bleeding (menorrhagia) where dienogest’s local endometrial effects may reduce bleeding. - Those dissatisfied with previous combined pills due to breakthrough bleeding or perceived metabolic changes. - Women who desire predictable cycle control and are comfortable with a dynamic (phasic) dosing schedule. - Absolute contraindications (do not prescribe if present) - Current or past history of venous thromboembolism (VTE) or known thrombophilia (e.g., Factor V Leiden with thrombosis). - Active or history of ischemic heart disease, stroke, or severe uncontrolled hypertension. - Migraine with aura (combined hormonal contraception is contraindicated). - Known or suspected pregnancy. - Active liver disease or liver tumor. - Known hypersensitivity to any component of the pill. - Relative contraindications / caution - Age >35 and smoking: increased cardiovascular risk. For smokers over 35, recommend non-estrogen options. - Family history of VTE: consider thrombophilia screening only if history or strong suspicion; otherwise evaluate risks. - Obesity: VTE risk increases with BMI; discuss risks and consider alternatives if multiple risk factors present. - Baseline assessment before initiation (practical checklist) - Obtain concise medical history: personal and family history of VTE, migraines (with/without aura), smoking status, hypertension, diabetes, liver disease. - Measure baseline blood pressure. - Calculate BMI and note any weight concerns. - Document current medications (enzyme-inducing drugs reduce efficacy). - Offer pregnancy test if there is any doubt about current pregnancy. - Discuss goals, side effects, and expectations—give written information and return plan. - Initiation options and counseling - First-day start: take the first active tablet on the first day of menses — immediate contraceptive protection. - Sunday or quick-start: start on the first Sunday after menses or start immediately — if not started in cycle day 1, advise backup contraception (condoms) for 7 days. - Switching from another combined pill: you can switch immediately the day after finishing the prior pack—no gap needed; if switching from progestin-only methods or postpartum/breastfeeding, follow specific guidance below. - Postpartum and breastfeeding: combined estrogen-containing pills are generally avoided in the first 6 weeks postpartum (or longer if risk factors) and are not recommended while exclusively breastfeeding due to potential, though small, effects on milk supply. Consider progestin-only options for breastfeeding women. Real example (patient selection): - Case A: 28-year-old non-smoker with heavy menstrual bleeding and prior good tolerance to combined pills — Qlaira is a suitable option. I explain potential benefits for bleeding control and start on cycle day 1 with immediate protection. - Case B: 36-year-old current smoker (10 cigarettes/day) with BMI 32 — I recommend against combined estrogen-containing contraception and discuss progestin-only or IUD options due to elevated cardiovascular risk. ## Managing side effects and counselling points (actionable) In practice, side effects are the main cause of discontinuation. Detailed pre-emptive counseling and clear stepwise management reduces unnecessary stopping. - Common and expected side effects - Breakthrough bleeding or spotting during the first 2–3 cycles: reassure that this often resolves by cycle 3. If persistent beyond 3 months, consider evaluation for non-adherence, uterine pathology (polyps, fibroids), or change method. - Breast tenderness, nausea, headache: usually transient; consider taking pill with food or at bedtime for first month. - Mood changes: track symptoms; if mood worsening is substantial, consider switching to another progestin formulation or a progestin-only method. - Specific actionable steps for common problems - Persistent irregular bleeding (>3 consecutive cycles): confirm adherence, review interacting medications (enzyme inducers), perform pelvic exam and ultrasound to rule out structural causes. If no cause, switch to another combined pill with different progestin or consider levonorgestrel IUD if heavy bleeding is the primary issue. - Weight concerns: discuss evidence — combined pills are not a proven cause of significant weight gain. Encourage lifestyle measures (diet, exercise). If patient attributes weight changes to the pill and is distressed, consider alternative methods. - Acne or androgenic symptoms: dienogest has antiandrogenic activity and may improve acne for many women. If worsening, reassess and consider switching. - Suspected thrombosis (leg pain/swelling, sudden chest pain, shortness of breath): stop pill immediately and seek emergency care. Explain signs at counseling visit. - Drug interactions and precautions - Enzyme-inducing drugs that reduce effectiveness: rifampicin/rifabutin, some antiepileptics (carbamazepine, phenytoin, topiramate >200 mg/day), certain antivirals. With these, additional or alternative contraception is required. - Antibiotics: most commonly used antibiotics (doxycycline, amoxicillin) do not significantly decrease combined pill effectiveness; rifampicin-like drugs do. - St. John’s wort (herbal): reduces contraceptive effectiveness — advise avoidance. - Interactions with lamotrigine: combined hormonal contraceptives can reduce lamotrigine levels; women with epilepsy should have neurology coordination. Practical example (side-effect management): - Ms. R, 31, started Qlaira and had intermittent spotting for 2 months. I reassured her, checked adherence and medications (no enzyme inducers), and scheduled a follow-up at 3 months. At 3 months bleeding persisted, ultrasound showed small submucosal fibroid; I discussed options and she chose an LNG-IUS for both contraception and bleeding control. - Monitoring after initiation - BP after 3 months and annually if stable. - No routine laboratory monitoring is required for most healthy women. - Review mood, bleeding pattern, adherence at 3 months, 6 months, and yearly. ## How Qlaira differs from ethinyl estradiol combined pills — clinical implications This section explains mechanistic and practical differences and how they translate into clinical decision-making. - Estrogen source - Many combined oral contraceptives (COCs) use ethinyl estradiol (EE), a synthetic estrogen with strong hepatic effects (increases certain clotting factors). - Qlaira contains estradiol valerate, a prodrug of 17β-estradiol (the endogenous estrogen). Because it is closer to physiological estrogen, it may have a different hepatic metabolite profile and potentially a different impact on lipids and coagulation. However, estradiol-containing combined pills still carry a risk of VTE; the absolute risk remains increased versus non-users. - Progestin component - Dienogest is a progestin with notable antiandrogenic and endometrial-stabilising properties. It can reduce menstrual blood loss and often improves dysmenorrhea and acne. - Clinically, dienogest-containing regimens can be particularly helpful for women whose principal complaint is heavy bleeding, while maintaining contraceptive efficacy. - Dosing regimen - Qlaira uses a dynamic (phasic) dosing schedule designed to mimic the natural cycle. Some women prefer this because they experience a monthly withdrawal bleed that feels more natural. Others prefer extended or continuous regimens for fewer bleeding episodes; discuss preferences and provide options. - VTE and cardiovascular risk: practical counseling - Absolute VTE risk in reproductive-age women on combined hormonal contraception is low but real. Counsel individual risk factors: age, obesity, smoking, family history, immobilization, surgery. - Discuss signs of VTE and when to seek emergency care. - If a patient is at higher baseline risk of thrombosis, progestin-only or IUD options are safer. ## Real-world prescribing scenarios and switching strategies Below I provide actionable switching protocols that I use in clinic, with patient-focused counseling statements that you can adapt. - Switching from another combined pill to Qlaira - Option A (seamless switch): Start Qlaira the day after finishing the previous active pack or the day following the tablet-free interval. No additional contraception needed if switching is done correctly. - Counseling line: “You can switch to Qlaira right away; start it the day after your old pack finishes. Use condoms for 7 days only if you don’t start on the first day of your period.” - Switching from a progestin-only pill (POP) or progestin implant/IUD - If switching from a POP to Qlaira, start Qlaira on the first day of next menses for immediate protection, or start any day and use backup for 7 days. - Removing an implant or IUD: you can insert a combined pill immediately if not pregnant; if fitted during the first 7 days of the cycle, no backup needed; otherwise use backup for 7 days. - Postpartum considerations - Non-breastfeeding: combined contraception can be started 21–28 days postpartum if no VTE risk factors; if earlier, use caution and counsel on VTE risk. - Breastfeeding: avoid combined pills for at least 6 weeks postpartum and consider progestin-only pills, implants, or IUD if contraception is required sooner. Real example (switching): - Ms. L used an ethinyl estradiol pill and reported more bloating and mood swings. After counselling, she switched to Qlaira with a seamless switch and reported improved bleeding patterns at 3 months and no worsening mood effects. ## FAQ ### What are the main advantages of Qlaira compared with traditional combined pills? Qlaira’s primary distinguishing features are the use of estradiol (a natural estrogen) and the progestin dienogest. Clinically, this can translate into: - Potentially lower hepatic metabolic impact compared with ethinyl estradiol—this may be relevant for lipids and markers of coagulation, although estradiol-containing combined pills still carry an increased VTE risk compared with non-use. - Improved control of heavy menstrual bleeding and dysmenorrhea because dienogest acts on the endometrium. - A dynamic dosing regimen that mimics the natural cycle, which some women find more acceptable. It’s important to balance these theoretical and clinical benefits with individual risk factors; Qlaira is not free of estrogen-related risks. ### How should patients manage a missed Qlaira tablet? Management depends on timing and the type of tablet missed. General practical rules I use and communicate: - If you miss one active tablet (<24 hours late), take it as soon as you remember and continue; no backup required. - If you miss two or more active tablets, or any tablets in the first week after starting the pack, take the most recent missed tablet as soon as possible (even if this means taking two at once), continue the pack, and use condoms or avoid sex for 7 days. If unprotected sex occurred in the previous 7 days, consider emergency contraception. - Always check the patient information leaflet for the pack-specific guidance and clarify at the dispensing visit. When in doubt, use backup methods and contact healthcare provider. ### Does Qlaira affect future fertility after stopping? No. Fertility typically returns rapidly after stopping combined oral contraceptives. Most women resume ovulatory cycles within a few weeks to months; many conceive in the first cycles after discontinuation. If conception does not occur within a year after stopping, evaluate for underlying infertility factors unrelated to prior combined pill use. ### Can women with acne or polycystic ovary syndrome (PCOS) use Qlaira? Yes, many combined pills improve acne due to estrogen’s increase in sex hormone-binding globulin and progestin antiandrogenic effects. Dienogest has antiandrogenic properties and can be beneficial for acne. For PCOS, combined pills are frequently used to regulate cycles, reduce androgens, and protect the endometrium in anovulatory cycles. However, the choice of pill should be individualized — for patients with significant metabolic concerns (obesity, insulin resistance), weight management and metabolic evaluation should accompany contraceptive choice. ### What should women with migraine do when considering Qlaira? Migraine requires careful assessment: - Migraine with aura: combined hormonal contraception is contraindicated due to increased stroke risk. Recommend progestin-only contraception or an IUD. - Migraine without aura: combined hormones are generally acceptable in younger, non-smoking women. Evaluate frequency and severity; if migraines worsen after initiation, reassess and consider alternatives. Always take a detailed headache history before prescribing combined hormonal contraception. ## Counseling scripts and practical advice I give patients (examples) - “If you forget a pill, take the most recent missed tablet now and continue. If it’s been more than 24 hours and you missed several, use condoms for a week.” - “If you develop sudden shortness of breath, sharp chest pain, or a swollen painful leg, stop the pill and seek emergency care — these can be signs of a clot.” - “If you smoke and are over 35, combined pills are not a safe option. We’ll look at alternatives like the progestin-only pill or an IUD.” I also provide printed information, direct them to our clinic [related topic](/blog) for deeper articles, and to our [shop](/shop) for non-prescription items like high-quality condoms and informational leaflets. ## When to change method or refer - Change method if: - Persistent unacceptable side effects after 3 months despite counseling. - Development of contraindications (e.g., new migraines with aura, significant prolonged immobilization, diagnosis of thrombophilia). - Refer to specialist if: - Recurrent or severe mood disorders triggered by hormonal contraception — consider integrated psychiatric and gynecologic care. - Complex bleeding disorders or suspected structural uterine pathology — refer to gynecologic imaging/surgery services when indicated. ## Final practical checklist for clinicians starting Qlaira - Review contraindications and risk factors (thrombosis, smoking, migraines). - Measure blood pressure and BMI. Offer baseline labs when clinically indicated (lipids, glucose) in patients with metabolic risk. - Choose start strategy (first-day start preferred for immediate protection). - Provide clear missed-pill instructions and discuss signs of VTE. - Schedule follow-up at 3 months to assess tolerance, bleeding pattern, and blood pressure. Category: Pregnancy ## FAQ ### Is Qlaira safer than pills that contain ethinyl estradiol? Qlaira contains estradiol valerate, a form of the natural estrogen 17β-estradiol, and this may be associated with a different hepatic metabolic profile than ethinyl estradiol. Some clinical data suggest a lower impact on certain metabolic markers, and there may be a different safety profile in terms of lipid and coagulation markers. However, combined estrogen–progestin contraceptives, including Qlaira, still increase the risk of VTE compared with non-users. “Safer” depends on an individual’s baseline cardiovascular and thrombotic risk — a personalized assessment is essential. ### Can Qlaira be used to treat heavy menstrual bleeding? Yes. Dienogest reduces endometrial proliferation and can reduce menstrual blood loss. For patients whose primary concern is heavy bleeding, Qlaira is a reasonable option and often produces lighter, shorter bleeding episodes. If bleeding is severe or due to structural causes (large fibroids, polyps), other interventions such as the levonorgestrel intrauterine system (LNG-IUS) may be considered and are highly effective. ### How long before Qlaira becomes effective as contraception? If started on the first day of bleeding (first day of menses), Qlaira provides immediate contraceptive protection. If started on another day of the cycle, use additional contraception (e.g., condoms) for 7 days. If switching directly from another combined product on schedule, no additional protection is necessary if done correctly. ### What monitoring do I need to do while on Qlaira? Routine blood tests are not required for most healthy women. Important monitoring includes blood pressure (baseline and periodically), assessment of bleeding patterns and mood, and vigilance for symptoms of VTE. In women with metabolic risk factors (diabetes, dyslipidemia), consider baseline and periodic monitoring of metabolic parameters as clinically indicated. ### Can Qlaira be used in breastfeeding women? Combined estrogen–progestin contraceptives are generally not recommended during early breastfeeding (first 6 weeks postpartum) because estrogens may slightly reduce milk production. Progestin-only options or non-hormonal methods are preferred while exclusively breastfeeding. After breastfeeding is well-established, combined methods may be considered based on individual risk assessment. --- If you’d like, I can prepare patient handouts you can print or email that summarize starting instructions, missed-pill management, and signs of complications — or a clinician quick-reference card for in‑clinic use.